DexCom, Inc.
DXCM
Ранг среди акций
#759
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Цена акции
$84.86
Рыночная капитализация
$32.02B
Изменение (1 день)
-1.03%
Изменение (1 год)
21.66%
Страна
US
Торговля DexCom, Inc. (DXCM)
Категория
Healthcare
Выручка компании DexCom, Inc. (DXCM)
Выручка на Jun 2026 TTM: $4.97B
Согласно последним финансовым отчетам DexCom, Inc., текущая выручка компании (TTM) составляет $4.97B. В 2024 году компания получила выручку $4.03B больше, чем выручке в 2023 году, которая составила $3.62B. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки DexCom, Inc. с 2000 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $4.97B | 6.59% |
| 2025 | $4.66B | 15.60% |
| 2024 | $4.03B | 11.34% |
| 2023 | $3.62B | 24.49% |
| 2022 | $2.91B | 18.84% |
| 2021 | $2.45B | 27.08% |
| 2020 | $1.93B | 30.54% |
| 2019 | $1.48B | 43.08% |
| 2018 | $1.03B | 43.58% |
| 2017 | $718.50M | 25.33% |
| 2016 | $573.30M | 42.61% |
| 2015 | $402.00M | 55.09% |
| 2014 | $259.20M | 62.00% |
| 2013 | $160.00M | 60.16% |
| 2012 | $99.90M | 30.99% |
| 2011 | $76.27M | 56.83% |
| 2010 | $48.63M | 63.78% |
| 2009 | $29.69M | 201.82% |
| 2008 | $9.84M | 112.62% |
| 2007 | $4.63M | 113.25% |
| 2006 | $2.17M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $46.59B | 837.47% |
US
|
|
| $35.48B | 614.08% |
IE
|
|
| $25.84B | 419.94% |
US
|
|
| $21.00B | 322.52% |
US
|
|
| - | - |
DE
|
